Passage Bio stock (US70267E1055): Cuts 75% of workforce after FDA feedback

Passage Bio slashed 75% of its staff amid FDA trial design requests for its frontotemporal dementia candidate, while exploring strategic alternatives, per recent reports.

Passage Bio, a clinical-stage genetic medicines company, recently announced significant workforce reductions, cutting 75% of its employees following FDA feedback on trial design for a key drug candidate targeting frontotemporal dementia and other central nervous system disorders. The move comes as the Philadelphia-based biotech explores strategic alternatives to refocus resources. BioSpace as of recent coverage.

Separately, Oppenheimer adjusted its price target on Passage Bio from $30 to $15 while maintaining an outperform rating, reflecting ongoing analyst interest despite challenges. The stock traded at around $5.96 recently, down 4.72% in a session, with a market cap of approximately $45 million as of early 2026 data. itiger as of 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Passage Bio, Inc.
• Sector/industry: Biotechnology / Genetic Medicines
• Headquarters/country: Philadelphia, Pennsylvania, USA
• Core markets: CNS disorders, rare diseases
• Key revenue drivers: Clinical-stage pipeline
• Home exchange/listing venue: Nasdaq (PASG)
• Trading currency: USD

Passage Bio: core business model

Passage Bio develops gene therapies for rare, monogenic central nervous system (CNS) disorders with high unmet needs, such as frontotemporal dementia. The company's AAV-based platforms aim to deliver transformative treatments where few options exist. With about 60 employees prior to cuts, it operates as a clinical-stage biotech focused on advancing candidates toward registrational trials. Headquarters in Philadelphia support US-centric operations relevant to Nasdaq-listed biotechs.

Main revenue and product drivers for Passage Bio

Passage Bio's pipeline centers on gene therapy candidates for CNS indications. Key programs target frontotemporal dementia, with recent FDA interactions on trial design prompting strategic shifts. No commercial revenues yet; value derives from clinical milestones, partnerships, and potential approvals. Analyst consensus targets average $13.25, implying upside from recent levels around $6, based on 7 Wall Street views as of 2026. MarketBeat as of 2026.

Industry trends and competitive position

The gene therapy sector for CNS disorders grows amid advances in AAV delivery, but faces regulatory hurdles and high costs. Passage Bio competes with larger players like Biogen in neurology, though its rare disease focus differentiates it. US investors track such firms for breakthrough potential in underserved markets.

Why Passage Bio matters for US investors

Listed on Nasdaq, Passage Bio offers exposure to innovative gene therapies targeting US-prevalent rare CNS diseases. Its Philadelphia base and FDA interactions align with domestic biotech trends, appealing to growth-oriented portfolios despite volatility.

Conclusion

Passage Bio navigates challenges with workforce cuts and FDA feedback while analysts maintain varied targets. Strategic reviews could shape its path in competitive gene therapy. Developments warrant monitoring for US investors eyeing biotech innovation.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.